Preclinical Landscape in Cancer Research

Auteur

Ranjita Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at the Free University of Berlin, Germany. Currently, she serves as Chief Scientific Officer (CSO) at Capnopharm GmbH, Germany. She has authored several research articles, book chapters, and presented her research in many national/international conferences. She has filed multiple patent applications in the area of drug delivery and targeting. Besides that, she has edited many trending books in the area of pharmaceutical nanotechnology and drug delivery aspects. For her research, she has received many prestigious national and international awards among them include recently received prestigious German Innovation Award 2022. Her areas of interest include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting and the role of excipients in delivery systems. (www.ranjitas.com)

Yashwant Pathak, is Professor and Associate Dean for the Faculty Affairs at the College of Pharmacy, at the University of South Florida. Tampa, USA. His area of research is in health care education, nanotechnology, drug delivery systems and nutraceuticals.

Texte du rabat
Preclinical Cancer Landscape *discusses the issues in preclinical-to-clinical translatability of molecularly targeted cancer therapies and the need to better align tumour biology in patients With a strong focus on the status, challenges, prospects and the need of robustness of preclinical cancer research, the book acknowledges that the bar for reproducibility in performing and presenting preclinical studies must be raised to facilitate a transparent discovery process that frequently and consistently leads to significant patient benefit. In 22 chapters this book describes the current status of preclinical research in multiple cancers. This book is a timely and valuable resource for health professionals, scientists and researchers, health practitioners, students, and all those who wish to broaden their knowledge in the allied field. " Preclinical landscape in cancer research "* is written by experts in the field and informed with facts directly from manufacturers. Pharmaceutical scientists, medical researchers, biomedical engineers and clinical professionals will find this an essential reference.

Contenu

1. Liver cancer: current status of preclinical research
   
   2. Pancreatic cancer: current status of preclinical research
   3. Heart cancer: current status of preclinical research
   4. Bone cancer: current status of preclinical research
   5. Spleen cancer: current status of preclinical research
   6. ENT cancer: current status of preclinical research
   7. Brain/CSN cancer: current status of preclinical research
   8. Skin cancer: current status of preclinical research
   9. Lung cancer: current status of preclinical research
   10. Thorax cancer: current status of preclinical research
   11. Thyroid cancer: current status of preclinical research
   12. Kidney-adrenal cancer: current status of preclinical research
   13. Urinary tracker cancer: current status of preclinical research
   14. Breast cancer: current status of preclinical research
   15. Blood cancer: current status of preclinical research
   16. Prostate cancer: current status of preclinical research
   17. Gynecologic cancer: current status of preclinical research
   18. Stomach and intestinal cancer: current status of preclinical research
   19. Plura and peritoneum cancer: current status of preclinical research
   20. Ocular cancer: current status of preclinical research
   21. Oral cancer: current status of preclinical research
   22. Growth Inhibitory Effects of Unsaturated Linoleinic Acid with Conjugated Double Bonds for Colon Cancer Prevention